Pepper Bio to Gain Exclusive Rights for Clinical Development of Lerociclib
G1 Therapeutics, Inc. has inked a global licensing agreement (excluding the Asia-Pacific region) with Pepper Bio for lerociclib for all indications except for certain radioprotectant uses.
Lerociclib | 03/05/2024 | By Aishwarya | 245
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy